Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Oncology and Biosimilar Sub-Report offers credible, relevant insights related to oncology (IV vs. oral) and biosimilar files to support a company’s reimbursement forecasting needs.
WHY DO YOU NEED THIS SUB-REPORT?
The CRaFT Oncology and Biosimilar Sub-Report provides analytic insights from trusted industry experts by offering critical measures on the oncology and biosimilar public market reimbursement process – from HTA submission to provincial listing.
WHAT DOES THE REPORT INCLUDE?
This CRaFT Oncology and Biosimilar Sub-Report includes 50+ page of insights on IV and oral oncology drugs related to:
CADTH review volume & timeline
pCPA volume for initiated, completed, closed, and not-negotiated files
pCPA under-consideration and under-negotiation timeline
Listing volume & timeline for each province
Market access timeline forecasting (from HTA submission to first listing)
It also includes biosimilar metrics related:
Oncology & non-oncology
Volume of funded biosimilars for each province
Average time to list for biosimilars for each province
Average time under negotiation for oncology & non-oncology biosimilars
For further information on the content and pricing of CRaFT and the Oncology and Biosimilar Sub-report, please complete your contact information on our main CRaFT Report page.